Full Press Release Details
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza (evinacumab) for Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH).
RARE
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza (evinacumab) for Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
Key Takeaway: Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza (evinacumab) for Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
Price reaction · baseline $47.95 (2024-01-03 close) · hit after-hours · 2 other RARE headline(s) in the window, move may be shared
day 0 close · peak
-1.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia